Savient Pharmaceuticals (SVNT) Inactive 10-K2003 FY Annual report

Filed: 12 Mar 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: absorption, accredited, ADAP, Alan, allergic, allopurinol, Alzheimer, ARB, Atlantic, back, Berna, bioavailability, bus, cannabinoid, capsaicin, Cardiome, carnitine, ceiling, CFO, cleared, compromised, contractor, Dear, difficultly, disposition, disseminate, DSM, economy, elucidating, embody, euro, eventual, febuxistat, Fleetwood, Florida, frame, France, front, Fulbright, furniture, Hall, hope, hyalurunate, hypothetical, IMS, inevitably, inflammation, insert, interaction, Internet, intolerant, investee, Ireland, issuer, Jaworski, judge, JV, landlord, leukemic, lost, Marco, margin, methodology, MHRA, mitigate, municipal, municipality, neurophilin, Nova, overstatement, owner, oxypurinol, Pharma, pharmacovigilance, pledged, posted, posting, postpone, prejudice, prerequisite, professional, purpose, ratio, reacquired, receptor, redesign, reintroduction, replied, reproducible, resale, residual, resold, retroactively, rheumatology, Rider, Rubinfeld, saleable, savient, Seton, slower, stem, step, stipulation, stockpile, stockpiled, substantive, succeed, sum, SVNT, Synvisc, Tatum, titration, transportation, Turkey, unamortized, uncollectible, uncontrolled, underperformance, underway, urology, user, verification, verified, viscosupplementation, Vitaquest, Viva, waiver, warfarin, worth, wound

Removed: admitted, advertising, affiliate, American, AML, amounting, analog, Antibiotici, assessed, asthma, authorized, BASF, Beecham, bGH, blinded, Bordeaux, bound, BPD, bronchopulmonary, cellular, compulsory, confidential, confirm, Consent, controlled, controller, corrected, counterclaimed, CPA, cytotoxic, department, desire, dismutase, Du, duly, dysplasia, enjoined, excrete, exhibit, Fish, focusing, generating, Haft, infeasible, Intercredit, Junior, Laser, Lechner, leukemia, lipodystrophy, listed, lung, mechanical, Missouri, Neave, omitted, oncology, OXSODROL, oxygen, Pennsylvania, placebo, Pont, postnatal, premature, preservation, Prodotti, promotional, protective, proved, reactivation, reactive, recently, redistribution, Reorganization, respiratory, returned, revealed, Robert, SAIZEN, Secretary, Serono, Shaw, SmithKline, Societa, SOD, Solchem, SPA, Sternlicht, stream, suggested, superoxide, Synnestvedt, Textile, thereunto, transmission, Trust, undersigned, undertook, ventilation, viral, Yeda, Yehuda

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SVNT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Savient Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan Rubinfield, Acting Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	Alan Rubinfeld
		Alan Rubinfeld
		Acting Chief Financial Officer and Treasurer
		March 12, 2004

A signed original of this written statement required by Section 906 has been provided to Savient Pharmaceuticals, Inc. and will be retained by Savient Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.